MLTX
MOONLAKE IMMUNOTHERAPEUTICSData as of 2026 Q2 (06-30) · 13F snapshot
Summary
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) is held as common stock by 5 tracked hedge-fund managers, with a combined reported value of ~$87.03M; the largest are Ken Griffin, Steven Cohen, Renaissance Technologies. 2 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 3 added, 2 trimmed. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Mixed
Common-stock holders52 also report options
Congress trades0
Price$11.56vs quarter-end-40.63%
Sectors0
This quarter's moves
Top holderNew0
Added3
Trimmed / sold2
Ken GriffinCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
| Investor | Value | % of portfolio | Action |
|---|
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $5.32M— of portfolio273,1002026 Q2
Value $4.12M— of portfolio211,8002026 Q2
Value $379.7K— of portfolio19,5002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $5.32M | — | — |
| Ken GriffinPUT | $4.12M | — | — |
| Paul Tudor JonesCALL | $379.7K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.